The Vioxx scandal, and the Food & Drug Administration’s (FDA) role in it, has not brought about much change at the agency, according to a new government report. Vioxx was approved for use in 1999, and quickly became a bestseller for Merck, with annual sales of $2.5 billion; however, the painkiller was pulled off the market [ ]
Merck Caught Misrepresenting Vioxx Risks Again
Although Merck has long maintained that the risks associated with Vioxx occur after long-term use, a recent study in the Canadian Medical Association Journal, says the drug may raise the risk of heart attack for patients taking Vioxx for less than 2 weeks.
MNCL: Cites Article on Arthritis Drug is Raising Some Concern
Martin Nutraceuticals Inc. (MNCL) cites a recent Canadian press article on Prexige, a member of the same drug class as Vioxx gaining Health Canada approval.
Merck Updates Vioxx Legal Saga
As the number of Vioxx-related cases mounts, Merck (MRK:NYSE - news - research) is discovering that some of its insurers don't want to pay for the company's defense against the lawsuits. Merck says it will fight the insurers' efforts to reduce or eliminate coverage.
Contact:
Copyright © 2005 Vioxx Advisor.com All Rights Reserved